Drug Trial Radar · NCT06704581
A Study of BGM0504 Injection in Participants With Obesity or Overweight
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
652
Actual
Start
Oct 29, 2024
Primary completion
Mar 17, 2026
Study completion Mar 17, 2026
Sponsor
- Lead sponsor
- BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
Conditions
- Overweight or Obesity
Interventions
5 mg BGM0504 injectionDrug
5mg BGM0504 injection administered subcutaneously (SC) once a week.
10 mg BGM0504 injection administered subcutaneously (SC) once a weekDrug
10mg BGM0504 injection administered subcutaneously (SC) once a week.
15 mg BGM0504 injectionDrug
15mg BGM0504 injection administered subcutaneously (SC) once a week.
BGM0504 placeboDrug
BGM0504 placebo administered SC once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline,Week 36
- Percentage of Participants Who Achieve≥5% Body Weight ReductionTime frame: Baseline,Week 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.